In mouse pre-clinical models and cancer patients, TIGIT expression on tumor-infiltrating CD8+ T cells often correlates with increased expression of other inhibitory receptors such as PD-1, LAG-3, TIM-3, and with decreased expression of DNAM-1 [115,119,120,121]. Here, CD226 is linked to neoplasm.